Geron (GERN) Corporate presentation summary

Strategic vision and financial guidance

• Targeting $220M–$240M in 2026 net product revenue for RYTELO, with disciplined operating expenses of $230M–$240M and plans to leverage the balance sheet for innovation.

• Expansion into relapsed/refractory myelofibrosis (R/R MF) is planned, contingent on positive Phase 3 ImpactMF trial results and regulatory approval, potentially doubling the addressable market.

RYTELO clinical profile and market positioning

• RYTELO is a first-in-class telomerase inhibitor approved in the U.S. and EU for lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia.

• Demonstrated 39.8% ≥8-week transfusion independence vs. 15% for placebo, with a median response duration of 52 weeks and a predictable, manageable safety profile.

• NCCN guidelines recommend imetelstat (RYTELO) as a preferred second-line treatment and as a first-line option for ESA-ineligible patients.

Scientific and clinical development

• Phase 3 IMerge trial showed durable transfusion independence and clinical benefit, with nearly half of responders experiencing almost a year without transfusions.

• Treatment-emergent cytopenias are associated with clinical response and are generally manageable, supporting an on-target effect.

• Ongoing pipeline includes studies in R/R MF, frontline MF, and AML, with key milestones expected in 2026 and 2028.